Allen Lapointe Nancy M, Sun Jie-Lena, Kaplan Sigal, d'Almada Phil, Al-Khatib Sana M
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Am J Cardiol. 2008 Apr 15;101(8):1134-41. doi: 10.1016/j.amjcard.2007.11.067. Epub 2008 Feb 7.
Little is presently known regarding whether a rhythm-control or a rate-control strategy is more frequently used in patients hospitalized for atrial fibrillation (AF). This study was conducted to assess patient and physician characteristics associated with each treatment strategy and with the use of anticoagulants. Hospitalizations for primary diagnoses of AF were examined using hospital claims from January 2000 to December 2004. Patients who received antiarrhythmic drugs, ablation, or cardioversion for AF were categorized as receiving rhythm control. Patients managed only with beta blockers, calcium channel blockers, or digoxin were categorized as receiving rate control. Characteristics associated with rhythm compared with rate control and anticoagulant use with CHADS(2) score were determined. The study cohort included 155,731 hospitalizations from 464 hospitals. Of these, 75,397 (48%) were categorized as involving rhythm control and 80,334 (52%) as involving rate control. Care by a noncardiologist (adjusted odds ratio [OR] 0.33, 95% confidence interval [CI] 0.31 to 0.36) and increasing age >65 years (adjusted OR 0.87, 95% CI 0.86 to 0.88) were associated with lower odds of rhythm versus rate control; hypertrophic cardiomyopathy was associated with greater odds (adjusted OR 2.3, 95% CI 1.81 to 2.84) of rhythm control. Warfarin use was greater in the rhythm-control group compared with the rate-control group (adjusted OR 1.56, 95% CI 1.52 to 1.60), and warfarin use was greater with a CHADS(2) score > or =2 (unadjusted OR 1.21, 95% CI 1.19 to 1.24). In conclusion, rhythm- and rate-control strategies were used equally in patients hospitalized for AF. Some observations, such as greater use of the rate-control strategy with increasing age, were consistent with recommendations, but others, such as lower use of warfarin in the rate-control group, were not.
目前,对于因心房颤动(AF)住院的患者,究竟是更常采用节律控制策略还是心率控制策略,人们所知甚少。本研究旨在评估与每种治疗策略以及抗凝剂使用相关的患者和医生特征。利用2000年1月至2004年12月期间的医院理赔数据,对以AF作为主要诊断的住院病例进行了研究。接受抗心律失常药物、消融治疗或房颤心脏复律的患者被归类为接受节律控制。仅使用β受体阻滞剂、钙通道阻滞剂或地高辛进行治疗的患者被归类为接受心率控制。确定了与节律控制相比心率控制相关的特征以及CHADS(2)评分与抗凝剂使用的关系。该研究队列包括来自464家医院的155,731例住院病例。其中,75,397例(48%)被归类为涉及节律控制,80,334例(52%)被归类为涉及心率控制。由非心脏病专家进行治疗(调整后的优势比[OR]为0.33,95%置信区间[CI]为0.31至0.36)以及年龄增加>65岁(调整后的OR为0.87,95%CI为0.86至0.88)与采用节律控制而非心率控制的较低几率相关;肥厚型心肌病与采用节律控制的较高几率(调整后的OR为2.3,95%CI为1.81至2.84)相关。与心率控制组相比,节律控制组华法林的使用更为普遍(调整后的OR为1.56,95%CI为1.52至1.60);CHADS(2)评分>或=2时华法林的使用更为普遍(未调整的OR为1.21,95%CI为1.19至1.24)。总之,因AF住院的患者使用节律控制和心率控制策略的情况相同。一些观察结果,如随着年龄增长心率控制策略的使用增加,与建议一致,但其他一些观察结果,如心率控制组华法林使用较少,则并非如此。